Certara (CERT) vs GoodRx (GDRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GoodRx (GDRX) has outperformed Certara (CERT) over the past year, losing 26.0% versus a loss of 30.7%. Over five years, CERT leads with a -76.3% price change compared with -92.3% for GDRX. Certara is the larger company by market cap ($1.37 billion vs $1.11 billion), about 1.2 times the size.
On valuation, GoodRx trades at a lower forward P/E (9.2x vs 23.0x for Certara).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CERT | GDRX |
|---|---|---|
| Share price | $8.96 | $3.25 |
| Market cap | $1.37B | $1.11B |
| 1-day change | -3.34% | -0.61% |
| YTD return | +1.70% | +19.93% |
| 1-year return | -30.70% | -25.97% |
| 5-year return | -76.32% | -92.34% |
| P/E ratio (TTM) | — | 65.00 |
| Forward P/E | 23.04 | 9.16 |
| EPS (TTM) | $-0.14 | $0.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.30 | $5.81 |
| 52-week low | $4.45 | $1.77 |
| Distance from 52-week high | -32.63% | -44.06% |
| Analyst consensus | buy | hold |
| Avg. price target upside | -3.79% | +21.54% |
| Average volume | 3.09M | 1.28M |
| Shares outstanding | 152.54M | 107.18M |
| Employees | 1,515 | 697 |
| Sector | Healthcare | Healthcare |
| Industry | Health Information Services | Health Information Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Certara
CERT stock →Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes.
Healthcare · Health Information Services · 1,515 employees
About GoodRx
GDRX stock →GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Healthcare · Health Information Services · 697 employees
CERT vs GDRX FAQ
Which is bigger, Certara or GoodRx?
Certara (CERT) is larger, with a market capitalization of $1.37B compared with $1.11B for GoodRx (GDRX).
Which stock has performed better over the past year, CERT or GDRX?
GDRX returned -25.97% over the past 12 months, compared with -30.70% for CERT (price return, excluding dividends). Past performance does not predict future results.
Are Certara and GoodRx in the same industry?
Yes. Both are classified in the Health Information Services industry within the Healthcare sector.